Peptide Library

Research statistics

Zilucoplan research: publications and trials

What has been published on Zilucoplan: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Zilucoplan works or is safe. For what it is and what the studies found, see the Zilucoplan profile.
Automated weekly refresh · data through November 1, 2026

At a glance

Publications, all years

62

Since 2020

Publications in 2026 so far

17

Through November 1, 2026

Human clinical research

43.1%

25 of 58 classified

Registered clinical trials

19

ClinicalTrials.gov

Randomized controlled trials

7

Publications reporting an RCT in people

Systematic reviews and meta-analyses

7

Preclinical studies

12.1%

2 animal · 3 in vitro · 2 computational

Records that only mention it

27

Not counted above

Status in the library: FDA-approved. 4 publications are not yet classified by study type.

Publications by year

Zilucoplan publications by year and evidence

2020, Human clinical research: 1 of 22020, Other and not yet classified: 1 of 22021, Preclinical (animal, in vitro, computational): 1 of 32021, Reviews and meta-analyses: 2 of 32022, Human clinical research: 1 of 52022, Preclinical (animal, in vitro, computational): 1 of 52022, Reviews and meta-analyses: 3 of 52023, Human clinical research: 2 of 62023, Preclinical (animal, in vitro, computational): 1 of 62023, Reviews and meta-analyses: 2 of 62023, Other and not yet classified: 1 of 62024, Human clinical research: 4 of 122024, Preclinical (animal, in vitro, computational): 1 of 122024, Reviews and meta-analyses: 5 of 122024, Other and not yet classified: 2 of 122025, Human clinical research: 10 of 172025, Preclinical (animal, in vitro, computational): 2 of 172025, Reviews and meta-analyses: 2 of 172025, Other and not yet classified: 3 of 172026 (to date), Human clinical research: 7 of 172026 (to date), Preclinical (animal, in vitro, computational): 1 of 172026 (to date), Reviews and meta-analyses: 3 of 172026 (to date), Other and not yet classified: 6 of 17Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified051015202020202220242026*
Counted PubMed publications by year of first publication. * 2026 runs to November 1, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
202010012
202101203
202211305
202321216
2024415212
20251022317
2026 (to date)713617

Study types

Review10
Case report8
Editorial, letter or other7
Randomized controlled trial7
Other clinical trial6
Observational human study4
Systematic review4
Not yet classified4
In vitro study3
Meta-analysis3
Animal study2
Computational study2
Correction or retraction notice2

Research areas

From MeSH major topics. A paper can be in several areas.

Immune system40
Neurological and mental health37
Oncology26
Antimicrobial and infectious disease4
Musculoskeletal3
Metabolic health1
Reproductive and sexual health1
Tissue repair1

Registered clinical trials

0 of 10 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 11 · Recruiting: 4 · Terminated: 2 · Active, not recruiting: 1 · Enrolling by invitation: 1
Phase not applicable: 1 · Phase 1: 2 · Phase 2: 6 · Phase 2 / Phase 3: 3 · Phase 3: 7

TrialStatusPhaseStartedResults
Zilucoplan for Severe gMG ExacerbationsNCT07215949 · 15 enrolledRecruitingPhase 32026-01—
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating WomenNCT06961747 · 15 enrolledRecruitingPhase 12025-07—
Effectiveness and Safety of Zilucoplan Treatment for French Patients With Myasthenia Gravis Over 3 MonthsNCT06815133 · 55 enrolledRecruitingPhase not applicable2025-03—
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisNCT06435312 · 8 enrolledEnrolling by invitationPhase 32024-11—
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisNCT06055959 · 8 enrolledRecruitingPhase 2, Phase 32024-10—
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia GravisNCT06471361 · 31 enrolledCompletedPhase 32024-08Posted
A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult ParticipantsNCT06511076 · 14 enrolledCompletedPhase 12024-08Posted
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 InhibitorsNCT05514873 · 26 enrolledCompletedPhase 32022-10Posted
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized PatientsNCT04590586 · 515 enrolledCompletedPhase 32020-11Posted
HEALEY ALS Platform Trial - Regimen A ZilucoplanNCT04436497 · 162 enrolledCompletedPhase 2, Phase 32020-07Posted
HEALEY ALS Platform Trial - Master ProtocolNCT04297683 · 1,500 enrolledActive, not recruitingPhase 2, Phase 32020-06—
Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory FailureNCT04382755 · 81 enrolledCompletedPhase 22020-05Posted
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisNCT04225871 · 200 enrolledCompletedPhase 32019-12—
Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing MyopathyNCT04025632 · 27 enrolledTerminatedPhase 22019-11Posted
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia GravisNCT04115293 · 174 enrolledCompletedPhase 32019-09Posted
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia GravisNCT03315130 · 45 enrolledCompletedPhase 22017-10Posted
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical StudyNCT03225287 · 19 enrolledTerminatedPhase 22017-07Posted
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to EculizumabNCT03030183 · 3 enrolledCompletedPhase 22017-04Posted
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH PatientsNCT03078582 · 26 enrolledCompletedPhase 22017-03Posted

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis.

    Journal of neurology · April 2, 2026 · Meta-analysis · cited 4 times

    PMID 41925914 · DOI 10.1007/s00415-026-13778-1 · Reviews and meta-analyses

  2. Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis.

    Advances in therapy · October 29, 2024 · Meta-analysis · cited 21 times · open access

    PMID 39470879 · DOI 10.1007/s12325-024-03014-5 · Reviews and meta-analyses

  3. Quantitative evaluation of drug efficacy in the treatment of myasthenia gravis.

    Expert opinion on investigational drugs · December 6, 2021 · Meta-analysis · cited 9 times

    PMID 34821184 · DOI 10.1080/13543784.2021.2010704 · Reviews and meta-analyses

  4. Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis.

    Current medical research and opinion · June 1, 2026 · Systematic review · cited 0 times · open access

    PMID 42495790 · DOI 10.1080/03007995.2026.2700048 · Reviews and meta-analyses

  5. Initiation response, maximized therapeutic efficacy, and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis.

    Frontiers in neurology · October 28, 2024 · Systematic review · cited 14 times · open access

    PMID 39529623 · DOI 10.3389/fneur.2024.1479685 · Reviews and meta-analyses

  6. The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis.

    CNS drugs · February 1, 2024 · Systematic review · cited 26 times

    PMID 38300476 · DOI 10.1007/s40263-024-01062-7 · Reviews and meta-analyses

  7. Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis.

    European journal of neurology · May 30, 2023 · Systematic review · cited 79 times · open access

    PMID 37204031 · DOI 10.1111/ene.15872 · Reviews and meta-analyses

  8. Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study.

    Journal of the neurological sciences · May 16, 2025 · Randomized controlled trial · cited 1 times · open access

    PMID 40450840 · DOI 10.1016/j.jns.2025.123550 · Human clinical research

  9. Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.

    JAMA network open · February 3, 2025 · Randomized controlled trial · cited 26 times · open access

    PMID 39960672 · DOI 10.1001/jamanetworkopen.2024.59058 · Human clinical research

  10. Improvement of fatigue in generalised myasthenia gravis with zilucoplan.

    Journal of neurology · February 24, 2024 · Randomized controlled trial · cited 14 times · open access

    PMID 38400914 · DOI 10.1007/s00415-024-12209-3 · Human clinical research

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.

    The Lancet. Neurology · May 1, 2023 · Randomized controlled trial · cited 282 times

    PMID 37059508 · DOI 10.1016/s1474-4422(23)00080-7 · Human clinical research

  2. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.

    JAMA neurology · May 1, 2020 · Randomized controlled trial · cited 198 times · open access

    PMID 32065623 · DOI 10.1001/jamaneurol.2019.5125 · Human clinical research

  3. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.

    Drugs · May 31, 2022 · Review · cited 130 times · open access

    PMID 35639288 · DOI 10.1007/s40265-022-01726-y · Reviews and meta-analyses

  4. Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis.

    European journal of neurology · May 30, 2023 · Systematic review · cited 79 times · open access

    PMID 37204031 · DOI 10.1111/ene.15872 · Reviews and meta-analyses

  5. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.

    Expert opinion on investigational drugs · April 1, 2021 · Review · cited 74 times · open access

    PMID 33792453 · DOI 10.1080/13543784.2021.1897567 · Reviews and meta-analyses

Latest publications

  1. Zilucoplan-Associated Morpheaform Skin Changes and Methotrexate and UVA1 Phototherapy.

    JAMA dermatology · October 1, 2026 · Not yet classified · cited 0 times

    PMID 42616491 · DOI 10.1001/jamadermatol.2026.2314 · Not yet classified

  2. Fibrosing Skin Disorder Associated With Zilucoplan.

    JAMA dermatology · October 1, 2026 · Not yet classified · cited 1 times

    PMID 42616530 · DOI 10.1001/jamadermatol.2026.2321 · Not yet classified

  3. Zilucoplan

    September 28, 2026 · Review · cited 0 times · open access

    PMID 42862928 · Reviews and meta-analyses

  4. Comparative Efficacy of Zilucoplan Versus Intravenous Immunoglobulin, Eculizumab, and Ravulizumab Using Matching-Adjusted Indirect Comparisons.

    Neurology and therapy · September 24, 2026 · Computational study · cited 0 times · open access

    PMID 42786374 · DOI 10.1007/s40120-026-01021-y · Computational studies

  5. Identifying molecular signatures underpinning treatment responses to novel therapeutics influencing COVID-19 outcomes.

    Journal of immunology (Baltimore, Md. : 1950) · August 1, 2026 · Other clinical trial · cited 0 times · open access

    PMID 42566685 · DOI 10.1093/jimmun/vkag189 · Human clinical research

  6. Case Report: Zilucoplan in refractory myasthenic crisis and its prodromal stages: a novel therapeutic perspective.

    Frontiers in neuroscience · July 29, 2026 · Case report · cited 0 times · open access

    PMID 42591413 · DOI 10.3389/fnins.2026.1886744 · Human clinical research

  7. Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences.

    Acta neurologica Belgica · July 17, 2026 · Editorial, letter or other · cited 0 times

    PMID 42467314 · DOI 10.1007/s13760-026-03109-6 · Commentary and other

  8. A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis.

    JAAD case reports · July 10, 2026 · Case report · cited 0 times · open access

    PMID 42604018 · DOI 10.1016/j.jdcr.2026.06.066 · Human clinical research

  9. Clinical efficacy and cost per improved outcome of treatments for generalized myasthenia gravis: evidence from a network meta-analysis and cost-per-responder analysis.

    Current medical research and opinion · June 1, 2026 · Systematic review · cited 0 times · open access

    PMID 42495790 · DOI 10.1080/03007995.2026.2700048 · Reviews and meta-analyses

  10. Combined inhibition of complement C5 and neonatal Fc receptor in refractory generalized myasthenia gravis: A report of two cases.

    Journal of neuroimmunology · April 21, 2026 · Case report · cited 3 times · open access

    PMID 42030590 · DOI 10.1016/j.jneuroim.2026.578944 · Human clinical research

Browse all 62 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: RA101495; Zilbrysq; Zilucoplan; Zilucoplan sodium

((TITLE_ABS:"RA101495" OR CHEM:"RA101495" OR TITLE_ABS:"RA 101495" OR CHEM:"RA 101495") OR (TITLE_ABS:"Zilbrysq" OR CHEM:"Zilbrysq") OR (TITLE_ABS:"Zilucoplan" OR CHEM:"Zilucoplan") OR (TITLE_ABS:"Zilucoplan sodium" OR CHEM:"Zilucoplan sodium")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 2). Zilucoplan research statistics (Version weekly-2026-11-01) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/zilucoplan